Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02877615
Other study ID # CL2-44819-004
Secondary ID 2016-001005-16UT
Status Completed
Phase Phase 2
First received
Last updated
Start date December 19, 2016
Est. completion date March 10, 2019

Study information

Verified date March 2020
Source Servier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of S 44819 in enhancing functional recovery after an ischemic stroke.


Recruitment information / eligibility

Status Completed
Enrollment 585
Est. completion date March 10, 2019
Est. primary completion date March 10, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion criteria :

- Patients aged between 18 and 85 years (both inclusive)

- Acute ischemic stroke that occured between 72 hours (3 days) and 192 hours (8 days) (both inclusive) before inclusion

Exclusion criteria :

- Any non-selection criteria, which could have occurred after the selection visit

- Positive urinary or blood pregnancy test (for female patients of child bearing potential)

- Any clinically significant findings from the local laboratory test likely to interfere with the ability to participate in the study and / or with the study outcome

- Severe renal impairment detected in the local laboratory test

- Severe hepatic impairment or liver enzymes abnormalities found in the local laboratory test

- Stroke due to cerebral venous thrombosis

- Brain MRI showing a severe microangiopathy

- Brain imaging showing an acute haemorrhagic stroke or a symptomatic haemorrhagic transformation of the brain infarct

- Qualifying ischemic cerebral event older than 192 hours at inclusion

- Any clinically relevant abnormalities detected during the examinations likely to interfere with study procedures or study outcome,

- Repeated prolongation of ECG QTcF

- Patient or authorised representative refusing to attend study visits or to take part in the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
S 44819 150 mg twice a day
One sachet of S 44819 150 mg and one sachet of placebo twice a day
S 44819 300 mg twice a day
Two sachets of S 44819 150 mg twice a day
Placebo
Two sachets of placebo twice a day

Locations

Country Name City State
Australia Royal Adelaide Hospital Department of Neurology Adelaide
Australia Sunshine Coast Hospital Birtinya
Australia Monash Medical Centre Department of Neurology Clayton
Australia Lyell McEwin Hospital Neurology Department Elizabeth Vale
Australia Gosford Hospital Neurosciences Department Gosford
Australia Austin Health Neurology Department Heidelberg
Australia Royal Brisbane & Women's Hospital Department of Neurology Herston
Australia Alfred Health Melbourne
Australia Royal Melbourne Hospital Department of Neurology Parkville
Australia Gold Coast University Hospital Southport
Belgium AZ Sint-Lucas Neurologie Brugge
Belgium AZ. St. Jan Brugge
Belgium Universitair Ziekenhuis Antwerpen Edegem
Belgium Jessa Ziekenhuis Dienst Neurologie Hasselt
Belgium UZ Leuven Campus Gasthuisberg Leuven
Belgium Les Cliniques Saint-Joseph Liege
Belgium Sint Andries Ziekenhuis Dienst Neurologie Tielt
Brazil Hospital das Clinicas da Faculdade de Medicina de Botucatu Botucatu
Brazil Clínica Neurológica e Neurocirúrgica de Joinville Joinville
Brazil Hospital Carlos Fernando Malzone Departamento de Neurologia Matão
Brazil Hospital Sao Lucas da Pontificia Universidade Catolica RS Setor de Pesquisa Clínica Porto Alegre
Brazil IMV Pesquisa Neurológica Setor de Pesquisa Clinica Porto Alegre
Brazil Hospital das Clinicas da Fac. de Med. de Ribeirao Preto Unidade de Emergencia - Centro de Estudo Ribeirao Preto
Brazil Hospital das Clinicas da Fac. de med. de Ribeirao Preto Unidade de Emergiancia Ribeirão Preto
Brazil Hospital Quinta D'or Departamento de Neurologia Rio de Janeiro
Brazil Irmandade Santa Casa de Misericordia de Sao Paulo Ambulatório de Neurologia Sao Paulo
Brazil UNIFESP - Universidade Federal de Sao Paulo Centro de Pesquisa em Neurologia Sao Paulo
Canada University of Alberta Edmonton
Canada Charles LeMoyne Hospital-CISSS de la Monteregie-Centre Greenfield Park
Canada Montreal General Hospital Montreal
Canada Saint John Regional Hospital Saint John
Czechia Fakultni nemocnice Brno Neurologicka klinika Brno
Czechia Fakultni nemocnice u sv. Anny Neurologicka klinika Brno
Czechia Nemocnice Jihlava Jihlava
Czechia Vseobecna fakultni nemocnice II. interni klinika VFN a 1. LF UK Praha
France CHU Bdx-Hôpital Pellegrin-Tripode Service de Neurologie Bordeaux
France Hôpital Sud-Francilien Unité Neurovasculaire Corbeil-essonnes
France CHU Henri Mondor Service de Neurologie Creteil
France CHU de Bicêtre Service de neurologie Le Kremlin-Bicêtre
France CHRU-Hôpital Roger Salengro Service de Neurologie Lille
France CHU-Hôpital Gui de Chaulliac Unité de Neuropshysiologie Clinique Montpellier
France Hôpital Lariboisière, Fernand-Vidal Service de Neurologie Paris
France Hôpital Sainte-Anne Service de Neurologie Paris
France CHU-Hôpital de la Milétrie Service de Neurologie Poitiers
Germany Klinikum Altenburger Land GmbH Neurologische Klinik Altenburg
Germany Neurologische Klinik GmbH, Bad Neustadt Bad Neustadt An Der Saale
Germany Vivantes Klinikum Neukölln Klinik für Neurologie mit Stroke Unit Berlin
Germany Universitätsklinikum Erlangen Neurologische Klinik Erlangen
Germany Universitaetsklinikum Essen Neurologische Universitätsklinik Essen Essen
Germany Universitätsmedizin der Johannes Gutenberg-Universität Klinik und Poliklinik für Mainz
Germany Johannes Wesling Klinik Minden Klinik für Neurologie Minden
Germany Kreisklinikum Siegen Klinik fuer Neurologie Siegen
Germany Universitätsklinik der Eberhard-Karls Universtiät Tübingen Hertie-Institut für Klinische Hirnforschung Tübingen
Germany Universitätsklinikum Ulm Neurologische Klinik (RKU) ULM
Hungary Bajcsy-Zsilinszky Korhaz es Rendelointezet Neurologiai Osztaly Budapest
Hungary Honved Korhaz Stroke reszleg Budapest
Hungary Orszagos Idegsebeszeti Tudomanyos Intezet Budapest
Hungary Semmelweis Egyetem Neurologiai Klinika Budapest
Hungary Szent Janos Korhaz Neurologiai osztaly Budapest
Hungary Petz Aladar Megyei Oktato Korhaz Neurologiai Osztaly Gyor
Hungary Somogy Megyei Kaposi Mor Oktato Korhaz Neurologiai Osztaly Kaposvár
Hungary Flor Ferenc Korhaz Neurologia Kistarcsa
Hungary B-A-Z Megyei Korhaz es Egyetemi Oktato Korhaz Stroke, Er- es Neurologiai, Toxikologiai Osztaly Miskolc
Hungary Kanizsai Dorottya Korhaz Neurologiai Osztaly Nagykanizsa
Hungary Josa Andras Oktatokorhaz Neurologiai Osztaly Nyiregyhaza
Hungary Pecsi Tudomanyegyetem Klinikai Kozpont Neurologiai Klinika Pecs
Hungary Soproni Erzsebet Oktato Korhaz Neurologiai Osztaly Sopron
Hungary Szegedi Tudomanyegyetem Szent-Gyorgy Albert Klinikai Kozpont Szeged
Italy Vito FAZZI U.O. semplice Stroke Unit Lecce
Italy Ospedale San Giuseppe UOC di Neurologia e Stroke Unit Milano
Italy Ospedale San Raffaele Milano
Italy Ospedale Sacro Cuore Don Calabria Negrar NEUROLOGY DEPT Negrar
Italy Istituto Neurologico mediterraneo NEUROMED Dipartimento di Medicina Riabilitativa e Specialistica Repar Pozzilli
Italy Policlinico Umberto I Emergency Department Stroke Unit Rome
Korea, Republic of Dong-A University Medical Center Department of Neurology Busan
Korea, Republic of Inje University Busan Paik Hospital Busan
Korea, Republic of Kyungpook National University Hospital Department of Neurology Daegu
Korea, Republic of Chonnam National University Hospital Department of Neurology Gwangju
Korea, Republic of Seoul National University Bundang Hospital Department of Orthopaedic Seongnam
Korea, Republic of ASAN Medical Center Department of Neurology Seoul
Korea, Republic of Kyung Hee University Hospital Seoul
Netherlands Zuyderland Medisch Centrum Afdeling Neurologie Heerlen
Netherlands Canisius Wilhelmina Ziekenhuis Afdeling Neurologie Nijmegen
Netherlands UMC St Radboud Afdeling Neurologie Nijmegen
Netherlands Erasmus MC Afdeling Neurologie Rotterdam
Netherlands Isala Klinieken Afdeling Neurologie Zwolle
Poland Samodzielny Publiczny Wojewodzki Szpital Specjalistyczny Oddzial Neurologiczny i Oddzial Udarowy Chelm
Poland M. Kopernika Provincial Specialist Hospital Dpt of Neurology Gdansk
Poland Samodzielny Publiczny Szpital Kliniczny nr7 SUM w Katowicach Oddzial Neurologii z Pododdzialem Udarowym Katowice
Poland Szpital Specjalistyczny sw. Lukasza Oddzial Neurologii i Oddzial Udarowy Konskie
Poland Miejskie Centrum Medyczne Jonscher Szpital Dr K. Jonschera Lodz
Poland Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie Oddzial Neurologii Lublin
Poland Wojewodzki Szpital Specjalistyczny SPZOZ nr 3 w Rybniku Rybnik
Poland Szpital Specjalistyczny Ducha Swietego w Sandomierzu Oddzial Neurologii Sandomierz
Poland Instytut Psychiatrii i Neurologii II Klinika Neurologiczna Warszawa
Spain H. General de Albacete Servicio de Neurología Albacete
Spain H. Germans Trias I Pujol Servicio de Neurología Badalona
Spain H. Clinic de Barcelona Comprehensive Stroke Center Barcelona
Spain H. del Mar Neurología Barcelona
Spain H. Valle de Hebrón Servicio de Neurología Barcelona
Spain Hospital Universitari de Bellvitge Servicio de Neurología-Unidad de Ictus-Planta 9 Barcelona
Spain H. Josep Trueta Servicio de Neurología Girona
Spain H. Ramón y Cajal Servicio de Neurología Madrid
Spain H. Universitario La Princesa Servicio de Neurología Madrid
Spain H. Universitario de Donosti Servicio de Neurología San Sebastian
Spain H. Virgen del Rocío Servicio de Neurología Sevilla
Spain Hospital Universitario La Fe Servicio de Neurología Valencia
Sweden Hassleholms Sjukhus Stroke- och rehabiliteringsavdelningen 9 Hassleholm
Sweden University Hospital Department of Neurology Linkoping
Sweden Skaraborgs Sjukhus Skovde Strokenheten Skovde
Sweden Danderyds Sjukhus Medicinmottagningen Stockholm
Sweden Akademiska Sjukhuset Strokeavdelningen 85B Uppsala
United Kingdom Royal United Hospital Older People's Unit Bath
United Kingdom Queen Elizabeth University Hospital Glasgow
United Kingdom Northwick Park Hospital Neurology Harrow
United Kingdom Leicester Royal Infirmary Dpt of Neurology Leicester
United Kingdom St George's University Hospitals Stroke Research office London
United Kingdom Nottingham City Hospital Nottingham
United Kingdom Poole NHS Foundation Trust Stroke Unit Poole
United Kingdom Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital Sheffield
United Kingdom Royal Stoke University Hospital Stroke Team Office Stoke on Trent

Sponsors (2)

Lead Sponsor Collaborator
Institut de Recherches Internationales Servier ADIR, a Servier Group company

Countries where clinical trial is conducted

Australia,  Belgium,  Brazil,  Canada,  Czechia,  France,  Germany,  Hungary,  Italy,  Korea, Republic of,  Netherlands,  Poland,  Spain,  Sweden,  United Kingdom, 

References & Publications (2)

Chabriat H, Bassetti CL, Marx U, Audoli-Inthavong ML, Sors A, Lambert E, Wattez M, Hermann DM; RESTORE BRAIN study investigators. Safety and efficacy of GABA(A) a5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomise — View Citation

Chabriat H, Bassetti CL, Marx U, Picarel-Blanchot F, Sors A, Gruget C, Saba B, Wattez M, Audoli ML, Hermann DM. Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study. Trials. 2020 Feb 3;21(1):136. doi: 10.1186/s13063-020-4072-2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Modified Rankin Scale (mRS) Up to 90 days
Secondary National Institutes of Health Stroke Scale (NIHSS) total score Efficacy criterion Selection visit Day 0 Day 5 Day 30 Day 60 Day 90 Day 105
Secondary Barthel Index (BI) total score Efficacy criterion Day 30 Day 60 Day 90 Day 105
Secondary Montreal Cognitive Assessment scale (Moca) total score Efficacy criterion Day 30 Day 90
Secondary Trail Making Test (TMT) time for part A Efficacy criterion Day 30 Day 90
Secondary Adverse events Safety criterion Through study completion, an average of 3 months
Secondary Suicidal ideation and suicidal behavior using the Columbia-Suicide Severity Rating Scale (C-SSRS) Safety criterion Day 5 Day 30 Day 60 Day 90 Day 105
Secondary Body weight Safety criterion Selection visit Day 30 Day 60 Day 90 Day 105
Secondary Vital signs (supine for Systolic and Diastolic Blood Pressure) Safety criterion Selection visit Day 0 Day 5 Day 30 Day 60 Day 90 Day 105
Secondary 12 lead-ECG Safety criterion Day 0 Day 5 Day 30 Day 60 Day 90 Day 105
Secondary Trail Making Test (TMT) time for part B Efficacy criterion Day 30 Day 90